This single center, retrospective study assessed the association between clinical parameters, tumor PD-L1 expression, molecular profiling and the development of thyroid irAEs in NSCLC patients treated with PD-1 or PD-L1 inhibitors. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.